CN103355665A - Composition for regulation of blood sugar level and adjunctive treatment of diabetes mellitus - Google Patents
Composition for regulation of blood sugar level and adjunctive treatment of diabetes mellitus Download PDFInfo
- Publication number
- CN103355665A CN103355665A CN2013101315540A CN201310131554A CN103355665A CN 103355665 A CN103355665 A CN 103355665A CN 2013101315540 A CN2013101315540 A CN 2013101315540A CN 201310131554 A CN201310131554 A CN 201310131554A CN 103355665 A CN103355665 A CN 103355665A
- Authority
- CN
- China
- Prior art keywords
- composition
- diabetes
- hypoglycemic
- resveratrol
- blood sugar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a composition for regulation of blood sugar level and adjunctive treatment of diabetes mellitus. The composition comprises the following components by weight percent: 10-70% of resveratrol, 10-50% of piperine, 10-70% of gamma-aminobutyric acid, and 0.01-5% of organic selenium. According to the composition, in the active ingredients, the resveratrol has the effects of regulating the blood sugar level and preventing oxidative stress of a body caused by the diabetes mellitus; the bioavailability of the resveratrol can be improved by the piperine; pancreas cell apoptosis is prevented and beta-cell palingenesis is facilitated by the gamma-aminobutyric acid; and the antioxidant ability of the body and glucose utilization are indirectly improved by the organic selenium participating into in vivo synthesis of glutathion peroxidase and deiodinase. By adopting the composition, the effects of the four raw materials are combined according to a certain dosage; and the functional food is prepared according to a certain component proportion, so that the four raw materials play respective effects in the process of preventing the diabetes mellitus.
Description
Affiliated technical field
The invention belongs to the functional food field, specifically, relate to a kind of hypoglycemic and composition adjuvant therapy of diabetes of having.
Background technology
Diabetes are human insulin hyposecretions or can not normally bring into play physiological action and the carbohydrate metabolism disturbance that causes causes a kind of chronic syndrome of the many kinds of substance metabolic disorders such as protein, fat, water, electrolyte then.The active immunity damage diabetes B patient that type 1 diabetes is derived from pancreatic beta cell has the insulin secretion ability, even may produce too much, but can not effectively play a role, and makes insulin may be in relative deficiency state.Diabetes B accounts for the diabetic more than 90%, how to fall ill after 35～40 years old, and public Community health has been produced very large harm.Diabetes cause hyperglycaemia and high free fatty acid (FFA), start oxidative stress, and the activation of oxidative stress signal path can cause insulin resistance (IR), insulin secretion is impaired and diabetic angiopathy.Oxidative stress not only participates in the morbidity of diabetes B, also consists of the pathogenesis of diabetic complications.The antioxidase level is lower in the pancreatic beta cell, to oxygen radical (ROS) sensitivity, therefore ROS can damage the β cell, promote its apoptosis, and indirectly suppress the β cell function by affecting Insulin signaling pathway, and the insulin secretion peak is postponed, be difficult to control the rapid rising of postprandial blood sugar.Prevention or the major measure of alleviating comprise: hypoglycemic, protect pancreatic beta cell and improve insulin action efficient (for diabetes B).
Some medicines have significant hypoglycemic activity, but adverse side effect (such as glucinan or α glucosidase inhibitor) also can appear in long-term taking.The blood-sugar decreasing active that has no side effect is one of importance of functional food research and development.The diabetes B slower development, at early period of origination, because compensatory insulin secretion, blood sugar is kept and normal physiologic values, hinders or postpone the diagnosis of the state of an illness.Simultaneously, can cause its exhaustion and degeneration to the chronic overstimulation of β cell, cause its insulin secretion ability to reduce gradually.Induce the temporary transient dormancy of β cell can improve its insulin secretion ability, thereby delay the development of diabetes B.But, at clinical practice insulin secretion inhibitor apparent side effect is arranged.The wholefood of exploitation adjusting insulin secretion is extremely important.Fat-reducing and energy limited (CR) diet are the important means that improves insulin sensitivity.CR is mainly by sirtuin1 (sirT1) regulation and control metabolism.Many people are difficult to adhere to strict CR, and the natural active matter that picked-up resveratrol etc. has the sirT1 activation can reach similar insulin sensitivity raising effect.
The hypoglycemic health food of China is more at present, such as medicine and food raw materials, Fructus Cucurbitae moschatae extract, Bitter Melon P.E, and propolis and Chroma-Pak etc.The food that has hypoglycemic, pancreas protection and insulin sensitivity raising effect concurrently rarely has existence, is the purpose that the present invention proposes and uses.
Summary of the invention
The object of the present invention is to provide a kind of food function factor composition for hypoglycemic, protection pancreatic beta cell, raising body insulin sensitivity and prevention diabetic complication, said composition effect of lowering blood sugar definite ingredients, steady quality has no side effect.
Solution of the present invention is based on understanding and principle hypoglycemic and the prevention diabetic complication, and to the understanding of resveratrol, GABA, Organic Selenium and pipering active function, achievement in research with reference to modern medicine, pharmacology and food function factor, go out to have raw material, science component hypoglycemic and prevention diabetic complication activity from numerous raw material screenings that contain, make its performance improve anti-sugar effect, replenish nutrient, anti-oxidant and improve the effect of blood vessel of diabetes patient.
A kind of for hypoglycemic and composition adjuvant therapy of diabetes, the composition and ratio that it is characterized in that forming said composition by weight percentage is:
According to claim 1 a kind of for hypoglycemic and composition adjuvant therapy of diabetes, the optimum ratio that it is characterized in that each constituent by weight percentage is:
In the above-mentioned composition composition, described resveratrol refers to the resveratrol that extracts from the plants such as giant knotweed and grape; Described pipering refers to from Fructus piperis nigrum extract, and main active matter is pipering; Described GABA (GABA) refers to employed gamma aminobutyric acid in drug additive, food additives and health food nutrient; Described Organic Selenium refers to the Organic Selenium replenishers such as employed Se-enriched yeast, selenomethionine in drug additive, food additives and health food nutrient.
Above-mentioned a kind of for hypoglycemic and composition adjuvant therapy of diabetes, its application forms is capsule, tablet, powder, electuary, paste or granule.
A kind of important feature of the present invention is that resveratrol (RES) is hypoglycemic, anti-oxidant and improve the mechanism of action of body insulin sensitivity.RES can regulate expression and the activity of glucose transporter, can be in the situation that lack insulin, promotion cellular uptake glucose.SirT1 can regulate and control deacetylation effect regulation and control sugar, the lipid metabolism of more than 20 kind of substrate; By in the insulin signaling transmission, in metabolic bypass, play a driving role, the insulin secretion that sirT1 stimulating pancreas β cell sugar relies on directly stimulates the insulin signaling Accessory tract in the organ of insulin sensitivity.Resveratrol is typical SirT1 activator, takes in the effect that doses can be brought into play similar CR.Studies show that, daily iron supplement 150mg left and right sides Bai Lilu can significantly reduce blood sugar.Because resveratrol seldom needs additionally to take in the right food.
Second characteristic of the present invention are to utilize pipering to improve the bioavailability of RES.The resveratrol 70% that human body is taken in is in intestinal epithelial cell generation glucuronidation and sulphation, and activity reduces greatly, only has 3.4% monomer can enter blood.Pipering is glucuronic acid desmoenzyme inhibitor in the effective intestines, and resveratrol share and can significantly improve its bioavailability.Pipering is derived from flavoring commonly used simultaneously, is the food additives (FEMA:2909) (Ministry of Public Health's bulletin 2004 No. 6) of China Ministry of Public Health approval, has no side effect, and can be used as the raw material of processing health food.
Pancreas β protection and palingenesis that the 3rd characteristics of the present invention are GABA.Injection GABA makes the cell membrane depolarising that can make the β cell, factor flow of calcium ions, thus activate the growth of PI3-K/Akt endogenous cell and survival signal path.Additional GABA can promote β cytothesis, thereby alleviates even the reverting diabetes state of an illness.Diabetes B patient blood GABA significantly reduces, and needs external source to replenish, and the content of GABA only is 0.3～32.5umol/g in the natural plant food, can not satisfy the human body needs, needs to replenish by functional food.
The 4th the anti-oxidant and blood sugar reducing function that characteristics are Organic Seleniums of the present invention.In the diabetes development later stage, patient's hypercatabolism, blood selenium level descends, and causes that 5 ' takes off the decline of iodine enzyme (selenoenzyme) biologically active, makes thyroxine transform reduction from T4 to T3, thereby reduces sugar decomposition.Selenium Supplement can promote glycometabolism by improving T3, thereby reduces blood sugar.Simultaneously; pancreas is the responsive organ of selenium deficiency; the activity of diabetic's blood GSH-PX activity peroxidase (GPX) lowers; GPX contains in its activated centre 4 gram atom selenium; the variation of selenium level is one of factor that affects this enzymatic activity in the body; lack selenium in the food and can cause that blood sugar increases, it is active that Selenium Supplement can improve GPX, and pancreatic cell is had protective effect.
The diabetes complex genesis, but that its prevention or mitigation strategy mainly comprise is hypoglycemic, protect pancreatic beta cell and improve insulin action efficient, and the present invention adopts the several functions raw material to carry out the science compatibility according to its main pathogenesis and counter-measure.Utilize RES and Organic Selenium to reduce blood sugar, improve insulin sensitivity; resist simultaneously oxidative stress; utilize GABA protection pancreatic beta cell; utilize pipering to improve the RES bioavailability; the effect that they can play is made up by certain law; and by certain component proportion, make functional food, make four kinds of raw materials in the process of hypoglycemic and prevention diabetic complication, give full play to each self-applying.The present invention proves to have obvious hypoglycemic function through the animal function test.
In addition, functional food functional component of the present invention is clear and definite, and steady quality is easy to control.The raw material components that the present invention selects is few, and flat flavor is easy to use, has no side effect.
Description of drawings
Fig. 1 is the mouse amount of drinking water.The record number of times is 14 times; The result is average ± standard deviation, different subscript significant differences, P＜0.05.
Fig. 2 is different disposal typical case mouse islets B eucaryotic cell structure.A is Normal group, and B is model control group, and C is the melbine processed group, and D is the composition high dose group, and E is dosage group in the composition, and F is the composition low dose group.
Fig. 3 is mice pancreatic pancreas islet number.The result is average ± standard deviation, different subscript significant differences, P＜0.05.
The present invention is further illustrated below in conjunction with specific implementation method and contractile studies.
The specific embodiment
The present invention will be described below to enumerate specific embodiment.It is pointed out that embodiment only for the invention will be further described, does not represent protection scope of the present invention, nonessential modification and adjustment that other people prompting according to the present invention is made still belong to protection scope of the present invention.
Embodiment 1
The composition and ratio of composition said composition by weight percentage is:
The composition and ratio of composition said composition by weight percentage is:
Embodiment 3
The composition and ratio of composition said composition by weight percentage is:
The composition and ratio of composition said composition by weight percentage is:
Above-described embodiment is used for the composition of hypoglycemic and adjuvant therapy of diabetes, by common process, can make said multiple formulation on the pharmacy, such as capsule, tablet, powder, electuary, paste or granule.
The animal function test
The powder that adopts above-described embodiment 1 prescription to make, carry out the animal function test according to Ministry of Public Health's " health food check and assessment technique standard (2003 editions) " regulation, freely drink water, the normal daily ration (Diet Formula sees Table 1) of searching for food is established one group of non-diabetic normal mouse (Normal group).With freshly prepared sodium citrate buffer solution (pH=4.5) dissolving alloxan (STZ) (0.1mol/L), the mouse fasting be can't help after the water 12 hours, with the STZ90mg/kg of preparation to mouse tail vein shot modeling.Recover feed after 72 hours the tail venous blood sampling survey blood sugar, with blood glucose value the mouse of 16～24mmol/L for becoming the mould animal.Blood glucose value according to Cheng Mo is divided into 8 groups with mouse, and every group of average blood sugar value approached, and 10 every group, five groups are respectively,
1) model control group: give diabetic mice gavage physiological saline 200ul/d;
2) positive controls (melbine group): give diabetic mice gavage melbine 600mg/kg/d;
3) resveratrol group is given diabetic mice gavage 15mg/kg bwd;
4) gamma aminobutyric acid group is given diabetic mice gavage gamma aminobutyric acid 1.0g/kg bwd;
5) Organic Selenium group, feed adds yeast selenium 60mg/kgbwd.
6) combination formula low dose group: execute example 1 compound composition 0.3g/kg bwd for the diabetic mice gavage;
7) dosage group in the combination formula: execute example 1 compound composition 0.6g/kg bwd for the diabetic mice gavage;
8) combination formula high dose group: execute example 1 compound composition 1.2/kgbwd for the diabetic mice gavage.
Table 1 experiment Diet Formula and trophic component (%)
Annotate: a trace element premix agent (agent of mg/0.06g trace element premix): FeSO4H2O, 15.3 (normally); CuSO4H2O, 1.676; MnSO4H2O, 15.225; ZnSO4H2O, 8.23; Na2SeO3,0.02823; KI, 0.040.B vitamin premix (mg/0.02g vitamin premix): thiamine, 0.6; Vitamin B2,0.6; Vitamin B6,0.7; Nicotinic acid, 3.0; Calcium pantothenate, 1.6; Folic acid, 0.2; Cobalamin, 0.001; Vitamin k, 0.005; Biotin, 0.02; Cholecalciferol, 0.0025; Vitamin A, 0.12; Vitamin E, 5.0.
Experimental result:
1, composition is on the impact of alloxan hyperglycaemia mouse amount of drinking water
From accompanying drawing 1 as seen, compare with normal control, there were significant differences (P＜0.05) for the amount of drinking water of model contrast, positive control and various dose composition group; Compare with model, there were significant differences for the amount of drinking water of high dose composition group (P＜0.05).Illustrating that positive drug, the present composition have alleviates the effect that diabetic mice is drunk symptom more, and dose-effect relationship.
2, composition is on the impact of alloxan hyperglycaemia Mouse Weight
As can be seen from Table 2, with when beginning body weight compare, the decline that the body weight of model control group continues shows the obvious characteristic of diabetes.And occur Body weight loss drug-treated group 1～2 week behind Cheng Mo, and all recover to some extent afterwards, illustrate that drug-treated has and alleviate the become thin effect of symptom of diabetic mice.Dosage composition group Mouse Weight recovers obvious than positive controls in wherein feeding, and illustrates that it shows the effect of certain diabetes-alleviating, and the effect of composition is better than the single treatment effect of resveratrol, gamma aminobutyric acid and Organic Selenium.
The variation of table 2, body weight (g)
Annotate: weight ratio is than ap＜0.05 when beginning on the same group; Contemporaneity and model compare bp＜0.05
3, composition is on the impact of alloxan hyperglycaemia mouse fasting blood-glucose
Table 3 shows, diabetic mice is two weeks behind Cheng Mo, the administration processed group and not the model control group mouse blood sugar a small amount of rising is all arranged.4th week chewable tablets processed group blood sugar descends to some extent, and model control group also continues to rise, and positive control processed group and the decline of composition high dose group blood sugar is (P＜0.05) significantly.Middle low dose group has downward trend, and all be lower than resveratrol, gamma aminobutyric acid and the independent processed group of Organic Selenium.
Table 3, mouse fasting blood-glucose (mmol/L)
Annotate: weight ratio when beginning on the same group
aP＜0.05; Contemporaneity and model compare
bP＜0.05
4, composition is on the impact of alloxan hyperglycaemia lipid of mice
The blood fat result shows in 4, compares with model contrast, give composition basic, normal, high three dosage group HDL-Cs obviously higher, T-CHOL is obviously lower, both all have remarkable significant difference (p＜0.05).And these two indicator and models contrasts of positive controls middle-high density lipoprotein cholesterol, T-CHOL are compared and no significant difference.Illustrate that also may there be increase diabetic mice HDL-C in composition, reduces total cholesterol level, regulates the effect of blood fat.
Table 4, lipid of mice
Annotate: data are mean+SD, and the different subscripts of same column represent significant difference P＜0.05
5, composition is on the impact of alloxan hyperglycaemia mice pancreatic tissue
Normal group pancreas look light red, irregular, and matter is soft.Model control group pancreas look pale, without obviously enlargement, in the matter.Positive control and compositions-treated group pancreas look light red are, irregular, and without obviously enlargement, matter is soft.Normal group pancreas clear in structure, every the visible 2-6 of section pancreas islet, average every has 4.6 pancreas islet.The atrophy of model control group pancreas islet or disappearance, every rarely seen 0 or 1 pancreas islet of section, average every has 0.5 pancreas islet.Positive controls pancreatic tissue structural integrity, every the visible 0-4 of section pancreas islet, average every has 2.0 pancreas islet.Various dose chewable tablets processed group pancreatic tissue structural integrity, every section visible 0-4 pancreas islet, pancreas islet be in various degree β cytothesis phenomenon as seen, degree relevant with dosage (accompanying drawing 2,3).
Claims (7)
1. composition that is used for hypoglycemic and adjuvant therapy of diabetes, the composition and ratio that it is characterized in that forming said composition by weight percentage is:
2. according to claim 1 a kind of for hypoglycemic and composition adjuvant therapy of diabetes, the optimum ratio that it is characterized in that each constituent by weight percentage is:
3. according to claim 1 and 2 a kind of for hypoglycemic and composition adjuvant therapy of diabetes, it is characterized in that described resveratrol refers to be extracted from the raw materials such as giant knotweed or grape.
4. according to claim 1 and 2 a kind of for hypoglycemic and composition adjuvant therapy of diabetes, it is characterized in that described pipering refers to be extracted from black pepper.
5. according to claim 1 and 2 a kind of for hypoglycemic and composition adjuvant therapy of diabetes, it is characterized in that described GABA refers to employed GABA in drug additive, food additives and health food.
6. according to claim 1 and 2 a kind of for hypoglycemic and composition adjuvant therapy of diabetes, it is characterized in that described Organic Selenium refers in drug additive, food additives and health food the Organic Selenium replenishers such as employed Se-enriched yeast.
7. according to claim 1 and 2 a kind of for hypoglycemic and composition adjuvant therapy of diabetes, the application forms that it is characterized in that said composition is capsule, tablet, powder, electuary, paste or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310131554.0A CN103355665B (en) | 2013-04-11 | 2013-04-11 | A kind of composition for auxiliary hyperglycemic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310131554.0A CN103355665B (en) | 2013-04-11 | 2013-04-11 | A kind of composition for auxiliary hyperglycemic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103355665A true CN103355665A (en) | 2013-10-23 |
| CN103355665B CN103355665B (en) | 2018-08-24 |
Family
ID=49358614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310131554.0A Active CN103355665B (en) | 2013-04-11 | 2013-04-11 | A kind of composition for auxiliary hyperglycemic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103355665B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112481314A (en) * | 2020-12-04 | 2021-03-12 | 江南大学 | Method for preparing inhibitor for inhibiting activities of alpha-amylase and glucosidase |
| CN116333302A (en) * | 2023-03-31 | 2023-06-27 | 中南大学 | Stable and durable antioxidant nano-dot and application thereof in type II diabetes |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101218977A (en) * | 2008-01-29 | 2008-07-16 | 杜道林 | Functional foods of pepper |
| CN101416957A (en) * | 2008-12-10 | 2009-04-29 | 山西亚宝药业集团股份有限公司 | Use of resveratrol or naringenin in preventing and treating diabetic nephropathy |
| CN101658537A (en) * | 2008-08-27 | 2010-03-03 | 安琪酵母股份有限公司 | Hypoglycemic ferment compound |
| WO2012145369A1 (en) * | 2011-04-22 | 2012-10-26 | Faerstein Paul Joseph | Compositions and methods for nutritional supplementation |
-
2013
- 2013-04-11 CN CN201310131554.0A patent/CN103355665B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101218977A (en) * | 2008-01-29 | 2008-07-16 | 杜道林 | Functional foods of pepper |
| CN101658537A (en) * | 2008-08-27 | 2010-03-03 | 安琪酵母股份有限公司 | Hypoglycemic ferment compound |
| CN101416957A (en) * | 2008-12-10 | 2009-04-29 | 山西亚宝药业集团股份有限公司 | Use of resveratrol or naringenin in preventing and treating diabetic nephropathy |
| WO2012145369A1 (en) * | 2011-04-22 | 2012-10-26 | Faerstein Paul Joseph | Compositions and methods for nutritional supplementation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112481314A (en) * | 2020-12-04 | 2021-03-12 | 江南大学 | Method for preparing inhibitor for inhibiting activities of alpha-amylase and glucosidase |
| CN116333302A (en) * | 2023-03-31 | 2023-06-27 | 中南大学 | Stable and durable antioxidant nano-dot and application thereof in type II diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103355665B (en) | 2018-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103238897B (en) | Composite plant solid drink suitable for diabetic patients | |
| US20080102137A1 (en) | Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization | |
| CN107812193B (en) | Pharmaceutical composition with alpha-glycosidase inhibitory activity and application thereof | |
| CN102366093A (en) | Composite slimming health food | |
| TWI636788B (en) | Use of parabacteroides goldsteinii to treat fatty liver disease | |
| CN113017089A (en) | Meal replacement composition for improving basal metabolism level and preparation method and application thereof | |
| KR20140090453A (en) | Composition comprising aronia extract for preventing and relieving hangover, and for protecting the alcohol-damaged hepatocyte | |
| Ismawanti et al. | The effects of papaya fruit as anti diabetes: A review | |
| Chaouachi et al. | A Review of the Health-Promoting Properties of Spirulina with a Focus on athletes’ Performance and Recovery | |
| CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
| CN103355665A (en) | Composition for regulation of blood sugar level and adjunctive treatment of diabetes mellitus | |
| CN107802770A (en) | Balance the Chinese medicine and health products of metabolic system radical cure early stage type II diabetes | |
| US9861676B2 (en) | Herbal composition and method of use | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN109122856A (en) | A kind of liver-protecting sober-up Chinese medicine composition | |
| CN104000877A (en) | Blood glucose reducing composition and application thereof | |
| CN104432068A (en) | Weight-losing health food | |
| CN115299542A (en) | Solid beverage with functions of improving intestinal function and preventing and treating constipation and application thereof | |
| CN114916661A (en) | Natural food composition and its application | |
| KR101692604B1 (en) | Composition comprising pomegranate juice extrated low speeed for improving liver function | |
| KR101465554B1 (en) | A functional food composition for triglyceride in blood and reducing inflammation level containing Methyl Sulfonyl Methane | |
| CN101306010B (en) | Function food for reducing the blood sugar and preventing diabetes complicating disease | |
| CN102228501B (en) | Chinese medicinal composition for resisting anoxia and fatigue and preparation method thereof | |
| CN105831730A (en) | Krill oil composite special dietary food for reducing hypertension, hyperglycemia and hyperlipidemia | |
| TWI612968B (en) | A use of an extract of asplenium australasicum (j. sm.) hook. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |